Pioneer REYON, Opening a New Paradigm
In-house R&D
In-house R&D
Co-development R&D
  • Antibody drugs
    - Other degenerative brain diseases such as Alzheimer's
  • AAV vector-based gene therapy
    AAV 벡터 기반 유전자 치료제
    - Acute neurological disease and neurodegenerative disease, etc.
  • Gene therapy platform technology
    유전자 치료제 플랫폼 기술
    - Gene transfer and increased expression in vivo
    - Co-development of ElectroPorator
    유전자 치료제 플랫폼 기술
    - Patented technology for gene transfer and increased expression in vivo
    - Development and production of normal human cell lines for biopharmaceutical research/production
  • Gene therapy drugs
    AAV 벡터 기반 유전자 치료제
    - Chronic renal failure and ischemic heart disease
  • Established cGMP-compliant manufacturing site for virus-based gene therapy drugs (USA)
    바이러스 기반 유전자치료제 cGMP 제조소 설립 (미국)
    - MOU for the establishment and operation of virus-based gene therapy drugs development/production-specialized manufacturing facility complying with cGMP
  • PDRN
    - Tissue regeneration (95% similar to human DNA)/PDRN-based specialty drug development and commercialization
  • Natural medicine, health functional food
    천연물의약품, 건강기능식품
    - Promoting new development through strategic cooperation between REYON Pharmaceutical, FINZELBERG, and G&P for various indications
  • Established virus vector business joint venture
    바이러스벡터 사업 JV설립
    - Signed MOU to establish joint venture for commercial production of virus vectors (lentivirus)